FindTrial
Sign In

study the effects of Cerebral perfusion pressure and Intracranial pressure targeted therapy in children with raised intracranial pressure and acute central nervous system infections.

A PILOT STUDY TO COMPARE THE OUTCOME OF CPP TARGETED THERAPY VERSUS ICP TARGETED THERAPY IN CHILDREN WITH ACUTE MENINGITIS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2012/05/002650
Enrollment
110
Registered
2012-05-14
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- RAISED INTRACRANIAL PRESSURE DUE TO ACUTE CNS INFECTIONS

Interventions

Intervention1: CEREBRAL PERFUSION PRESSURE TARGETED THERAPY: CEREBRAL PERFUSION PRESSURE WILL MAINTAINED ABOVE 60 MMHG WITH HELP OF FLUID AND VASOACTIVE THERAPY AND MEASURE TO REDUCE THE ICP Control I

Sponsors

ADVANCED PEDIATRIC CENTRE
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Child aged 1 to 12 years presenting with raised ICP (clinical signs or on CT head -3. Clinically changes in heart rate (tachycardia/bradycardia) hyperventilation, posturing, unequal pupils, brisk DTR, upgoing plantar and/or papilloedema. On neuroimaging (CT/MRI) when available - loss of sulci, slit like ventricle, loss of grey/white distinction, obliteration of suprasellar and quadrigeminal cistern or presence of brain herniation syndromes) was taken as evidence of raised ICP )7 due to acute CNS infections and m-GCS 2. 4. Written informed consent from parents or legal guardian

Exclusion criteria

Exclusion criteria: 1. Patients with raised ICP due to causes other than acute CNS infections[traumatic brain injury, subarachnoid hemorrhage, epidural or subdural hematoma, hydrocephalus, CNS tumors on neuroimaging, hypertensive encephalopathy]. 2. Contraindications to insertion of ICP transducer because of coagulopathy, infection at the site of insertion, subdural and epidural infection. 3. Neurodevelopmental delay or chronic neurological illness. 4. History of illness more than 7days of duration. 5. Clinical brain death as specified by human organ transplant act 1994

Design outcomes

Primary

MeasureTime frame
(1) m-GCS at 72 hours after-enrolment (2) mortality at PICU discharge and 90 days after discharge.Timepoint: (1)72 hours after-enrolment (2) 90 days after discharge.—

Secondary

MeasureTime frame
Functional status as per Pediatric Cerebral Performance Category (PCPC) scaleTimepoint: at discharge and at 3 months and 3monthly in 1st year and 6monthly in 2 to 5year—

Countries

India

Contacts

Public ContactProfSUNIT SINGHI

APC, PGIMER

sunit.singhi@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 8, 2026